¥ 2473.5
Key Takeaways
Risk factor
Negligible price volatility
Profitability factor
Very strong margins and returns
About
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for...
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on
Target Price
The average target price of 4507.T is 2586 and suggests 6% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
